New Delhi: Anixa Biosciences, Inc., a biotechnology company focused on using the body’s immune system to fight cancer, recently announced that it has extended and expanded its collaboration with New Jersey Urology, LLC (“NJU”).
Pursuant to the extension, NJU will continue to provide patient samples for Anixa’s ongoing Cchek early cancer detection study. Further, the collaboration has been expanded to include support of clinical validation of Anixa’s Cchek Prostate Cancer Confirmation test with Anixa’s commercialization partner, ResearchDx.
Dr Adam Perzin, who will continue to serve as the Principal Investigator at NJU for the study, stated, “We’re excited about expanding our collaboration and helping Anixa towards commercialization of this test, as the PSA test for prostate cancer is not ideal.”
“NJU continues to be a key collaborator in the development of Cchek, our artificial intelligence-driven liquid biopsy for early cancer detection, and we are pleased that this collaboration has been extended,” stated Dr Amit Kumar, CEO of Anixa. “Further, we look forward to NJU’s participation as we begin the clinical validation phase of Cchek in preparation for the commercial launch of our Cchek Prostate Cancer Confirmation test in the third quarter of this year,” added Dr Kumar.
NJU, through its April 2018 merger with Delaware Valley Urology, has been a collaborator of Anixa Biosciences’ since March 2017. NJU is the largest urology group in the United States, with nearly 100 physicians practicing at more than 40 locations within the state of New Jersey focusing on the advanced diagnosis and treatment of urological conditions including benign prostate conditions and prostate cancer.